Verified Supplement Data Primary-sourced

CLA for Fat Loss: Realistic Expectations Before You Buy

By Erin Rose · Updated · Methodology

Educational summary — not medical advice. CLA is not a treatment for obesity or a substitute for diet and exercise; anyone with diabetes, prediabetes, or metabolic syndrome should read the trade-off section below before trying it. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

The honest answer

At the 3.2 g/day studied dose, CLA produces about 0.09 kg (0.2 lb) per week of fat loss versus placebo — roughly a pound or two over 12 weeks, and the effect plateaus rather than compounding (Whigham 2007). That's real, but small. And it comes paired with a real trade-off: several trials found CLA worsens insulin sensitivity and lowers HDL in the exact population — obese, metabolic-syndrome-prone — most likely to try it for this reason (Risérus 2002).

What "0.09 kg/week" actually means over 12 weeks

Marketing copy for fat-loss supplements tends to round vague effects up into confident promises. Here's the actual math, from the largest pooled human dataset available: at the 3.2 g/day dose most studied, Whigham 2007's meta-analysis of 18 randomized, placebo-controlled trials found a dose-response fat-loss effect of about 0.09 kg per week versus placebo (P<0.001). Run that forward across a typical 12-week supplement trial or a 3-month "give it a try" window, and you land at a little over 1 kg (roughly 2–2.5 lb) — if the weekly rate held constant, which it doesn't past the early months. The pooled data shows the effect is linear only up to about 6 months, then plateaus toward an asymptote by around 2 years. In practice: expect a small, front-loaded effect that tapers, not a steady month-over-month burn.

TimeframeWhat the pooled data suggestsThe honest caveat
First ~12 weeksRoughly 1–1.5 kg (2–3 lb) fat loss vs. placebo, at the ~3.2 g/day median doseBased on a linear extrapolation of the weekly rate; individual results vary widely across the pooled trials
6 monthsEffect approaching the top of its rangeThe dose-response relationship is linear only up to about here (Whigham 2007)
1–2 yearsEffect plateaus toward an asymptoteContinued use does not appear to keep compounding the benefit

A separate, longer-duration meta-analysis pooling 7 trials of 6+ months found a statistically significant but small 1.33 kg fat-mass difference favoring CLA (Onakpoya 2012) — and its own authors concluded "the magnitude of these effects is small, and the clinical relevance is uncertain," going on to state that the evidence "does not convincingly show that CLA intake generates any clinically relevant effects on body composition on the long term." That is about as clear a caution as a systematic review offers.

The trade-off, in the same breath as the benefit Any realistic expectation for CLA's fat-loss effect has to sit next to this: several controlled trials found CLA — especially the trans-10,cis-12 isomer, and in one trial a standard 50:50 blend too — worsened insulin sensitivity and raised fasting glucose in obese, metabolic-syndrome, or type-2-diabetic participants (Risérus 2002; Moloney 2004), and lowered HDL cholesterol in Risérus 2002 (though Moloney 2004 saw HDL rise). That is precisely the population most likely to reach for a fat-loss supplement. Weigh a possible pound or two of fat loss against a real, trial-documented metabolic-risk signal — don't consider the fat-loss number alone. See the full trial-by-trial breakdown.

Not a substitute for diet and exercise

Every trial behind these numbers layered CLA onto participants' existing diet and activity levels — none tested it as a replacement for either. A sustained calorie deficit or a structured exercise program routinely produces fat-loss results several times larger than CLA's measured effect. If your goal is meaningful fat loss, CLA is, at best, a minor adjunct on top of those fundamentals — not a shortcut around them, and not something to expect visible results from on its own.

Who this is (and isn't) reasonable for

  • People with realistic expectations — a small, plateauing effect on top of an existing diet and exercise routine, not a standalone fat-loss strategy.
  • Not reasonable for anyone with diabetes, prediabetes, or metabolic syndrome without first reading the metabolic-risk trade-off — that is the population the adverse glucose/insulin signal was measured in.
  • Not a substitute for a calorie deficit, resistance training, or medical treatment for obesity.
  • If you decide to try it anyway, dose to the ~3.2 g/day studied range and see best CLA for products that actually reach it.

Compare CLA Products

If you're ready to buy, here's how the CLA products we track and verify compare on cost per gram.

Ranked by cost per day, lowest first — from the Verified Supplement Data catalog, prices reviewed August 2026.
ProductDose/ServingServingsPriceCost/DayCertificationBuy
BulkSupplements.com CLA Softgels 1000mg
2000mg CLA150$23.97$0.16None statedBuy on Amazon
Nutricost CLA 800mg
2400mg CLA80$16.95$0.21None statedBuy on Amazon
Zazzee High Potency CLA 3600
3600mg CLA60$19.97$0.33None statedBuy on Amazon
Sports Research CLA 1250mg (Tonalin)3750mg CLA60$26.95$0.45None statedBuy on Amazon
The Vitamin Shoppe Tonalin CLA 1000mg3000mg CLA60$34.97$0.58None statedBuy on Amazon

Frequently asked questions

How much fat will I actually lose?

About 0.09 kg (0.2 lb)/week at the 3.2 g/day dose (Whigham 2007) — roughly a pound or two over 12 weeks, plateauing by ~6 months. A longer meta-analysis found ~1.33 kg over 6+ months with "uncertain" clinical relevance (Onakpoya 2012).

Why does the effect plateau?

The pooled data is linear only to ~6 months, then approaches an asymptote by ~2 years (Whigham 2007) — continued use doesn't appear to keep compounding the benefit.

Should I take CLA instead of dieting or exercising?

No. Every trial layered CLA onto existing diet/exercise; none tested it as a replacement. The effect is far smaller than what diet or exercise alone produces.

What's the trade-off?

Several trials found CLA worsens insulin sensitivity and lowers HDL in obese/metabolic-syndrome/diabetic populations — the same people most likely to try it for fat loss. Weigh that against the small expected benefit.

Related

Sources

  1. Whigham LD, Watras AC, Schoeller DA. "Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans." Am J Clin Nutr. 2007. PMID: 17490954
  2. Onakpoya IJ, Posadzki PP, Watson LK, Davies LA, Ernst E. "The efficacy of long-term conjugated linoleic acid (CLA) supplementation on body composition in overweight and obese individuals: a systematic review and meta-analysis of randomized clinical trials." Eur J Nutr. 2012. PMID: 21990002
  3. Risérus U, Arner P, Brismar K, Vessby B. "Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome." Diabetes Care. 2002. PMID: 12196420
  4. Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. "Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus." Am J Clin Nutr. 2004. PMID: 15447895